Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWD8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,212
Award facts
- Contract value 100% obligated
- $26,211.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $26,211.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. The delivery order, issued on November 24, 2025, with an ultimate completion date of December 16, 2025, was made without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a broader $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for pharmaceutical supply across the Department of Defense.
The PPV-G GEN V contract, designated as SPE2DR and awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, structured with a 30-month base period and three optional 30-month renewal periods. DMS Pharmaceutical Group's established portfolio includes a comprehensive range of pharmaceuticals spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support military healthcare facilities worldwide. The contractor's substantial recent federal contracting activity and consistent performance across multiple therapeutic categories position it as a critical supplier within the Department of Defense's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQWD8?
SPE2DR26FQWD8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FQWD8 worth?
The government has obligated $26,212 on SPE2DR26FQWD8.
Is contract SPE2DR26FQWD8 an order under another contract?
Yes. SPE2DR26FQWD8 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWD8 competed?
The extent of competition for SPE2DR26FQWD8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award